Shares of Synta Pharma (NASDAQ: SNTA) declined after the company presented Galaxy 1 data and "non standard" enrollment criteria for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE